002630 — Orient Bio Balance Sheet
0.000.00%
- KR₩78bn
- KR₩49bn
- KR₩29bn
Annual balance sheet for Orient Bio, fiscal year end - March 31st, KRW millions except per share, conversion factor applied.
R2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Interim Report | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 10,940 | 58,244 | 29,396 | 35,958 | 27,265 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 9,421 | 6,676 | 8,210 | 13,827 | 10,057 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 29,060 | 70,498 | 49,250 | 58,984 | 47,415 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 31,321 | 18,319 | 15,857 | 17,463 | 20,516 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 71,519 | 104,952 | 81,050 | 96,988 | 84,782 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 15,230 | 13,644 | 3,892 | 4,207 | 4,211 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 22,974 | 21,764 | 9,658 | 11,892 | 12,935 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 48,545 | 83,188 | 71,392 | 85,096 | 71,847 |
| Total Liabilities & Shareholders' Equity | 71,519 | 104,952 | 81,050 | 96,988 | 84,782 |
| Total Common Shares Outstanding |